Wire · opportunities
FDA Approves Revolution-ary New Drug for Pancreatic Cancer
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 27 August 2026 · Fusion42 review
The U.S. FDA approved daraxonrasib (Rasonque), a new targeted oral therapy that nearly doubled survival time for metastatic pancreatic cancer patients after previous treatment, with accelerated approval granted 135 days after data submission.
This Wire brief sits within Fusion42's coverage of Biotech, and 32 sources have reported it between 26 Aug 2026 and 27 Aug 2026.
◆ ◆ The Wire takeaway
You face a new commercial and clinical pathway opening as pancreatic cancer treatment advances with a FDA-approved oral drug that extends patient survival significantly. Act now to align your biotech or healthtech strategy with this breakthrough drug's market entry.
◆ Coverage
32 sources · first reported 26 Aug 2026 · latest 27 Aug 2026
◆ Topics